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We report herein the case of a patient successfully treated by transhepatic portal venous stent placement for malignant portal vein
obstruction with associated gastric and small bowel varices and repeated gastrointestinal bleeding. CT angiography and portogra-
phy showed severe portal vein obstruction from recurrent pancreatic cancer 15 months following pancreaticoduodenectomy with
tumor encasement and dilated collateral veins throughout the gastric and proximal small bowel wall as the suspected cause of the
GI bleeding. Successful transhepatic endovascular stent placement of the splenic vein at the portal vein conﬂuence followed by
balloon dilation was performed with immediate decompression of the gastric and small bowel varices and relief of GI hemorrhage
in this patient until his death four months later. The treatment for patients with this dilemma can prove to be diﬃcult, but as we
have shown endovascular stenting of the portal system is an eﬀective treatment option.
Copyright © 2009 Christian M. Ellis et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Pancreatic cancer remains a major oncologic challenge
making up 2% of all new cancer cases and 6% of cancer
deathsintheUnitedStates[1].Althoughsomecancercenters
report up to 20% 5-year survival rate after pancreaticoduo-
denectomy, the outlook, morbidity, and mortality for this
disease remain bleak [2]. Therefore, in patients who develop
recurrent metastatic disease, new methods of treatment
and palliation are necessary to improve their quality of
life. In cases of malignant portal venous obstruction from
tumor, such as in hepatocellular carcinoma, cholangiocar-
cinoma, and pancreatic cancer endovascular stents have
demonstrated the ability to relieve symptoms associated
with this type of presentation [3]. We report the case of a
patient after pancreaticoduodenectomy who developed near
complete splenic vein obstruction with symptomatic gastric
and small bowel mesenteric varices that was revascularized
by transhepatic placement of an endovascular stent into the
splenic vein (SV) at the portal vein (PV) conﬂuence.
2.CaseReport
A 58-year-old man was referred to our institution for a
suspicious mass within the neck of the pancreas with a
dilated pancreatic duct and evidence of chronic pancreatitis
identiﬁed by abdominal computed tomography (CT). An
endoscopic ultrasound (EUS) and endoscopic retrograde
cholangiopancreatography (ERCP) identiﬁed adult diag-
nosed pancreatic divisum with a 2.5cm mass within the neck
of the pancreas and pancreatic duct stricture. A ﬁne needle
aspiration (FNA) of this area showed only chronic inﬂam-
mation and a CA 19-9 level returned within normal limits.
Review at our institutional multidisciplinary conference led
to recommendations for surgical resection, and ten months
after his initial presenting symptoms, the patient underwent
a pylorus-preserving pancreaticoduodenectomy. The ﬁnal
pathology revealed a specimen with chronic pancreatitis
and one small focus of invasive carcinoma with perineural
invasion. No tumor was identiﬁed in twenty-one lymph
nodes. All surgical margins were negative for tumor. The
patient made an uneventful recovery and afterward elected
to forego any further adjuvant treatments.
The patient did well while undergoing routine surveil-
lance until approximately 15 months later when he began
to experience mild to moderate abdominal discomfort and
nausea. A repeat CT scan of the abdomen revealed a mass
at the site of the previous surgical resection with narrowing
of the PV conﬂuence and extensive lymphadenopathy at
the root of the mesentery. An ultrasound-guided biopsy of2 HPB Surgery
Figure 1: CT evidence of the recurrent pancreatic mass in
the previous surgical bed (large arrow) and demonstration of
obstruction of the splenic vein at the portal vein conﬂuence (small
arrow).
this area conﬁrmed recurrent well-diﬀerentiated adenocarci-
noma, and the patient began concurrent chemoradiotherapy
with continuous infusion 5-ﬂuorouracil and external beam
radiation therapy (EBRT) for a total dose of 54Gy.
On follow-up the patient developed upper gastrointesti-
nal(GI)bleeding,requiringmultiplebloodtransfusions,and
on upper endoscopy was found to be due to varices of the
proximal gastric wall, which appeared to extended through
the anastamosis into the eﬀerent jejunal limb. At the time
of endoscopy there was no evidence of active bleeding, and
so we elected to proceed with medical management for the
patient to include β-blockers and intravenous octreotide.
During the same hospitalization the patient again devel-
oped variceal bleeding. We found that the recurrent pancre-
atictumorhadcausedahigh-gradeneoplasticobstructionof
the SV at the PV conﬂuence and as a consequence resulted in
mesenteric hypertension and gastric and small bowel varices
that were refractory to our medical management (Figures 1,
2,a n d3). Because of this treatment dilemma we sought
the expertise of our interventional radiology department
who conﬁrmed the SV obstruction and dilated varices by
transhepatic portography (Figure 4). They were then able to
successfully treat the patient by transhepatic endovascular
stenting of the SV obstruction with a 10mm × 42mm
wall stent followed by an 8mm balloon dilation. Repeat
splenic venography demonstrated the PV conﬂuence to be
patent with good ﬂow across the stent along with dramatic
decompression of the collateral gastric and small bowel
varices (Figure 5).
Immediately after the procedure the patient had no addi-
tional episodes of melena or hematemesis, and no further
blood transfusions were required. Seven days following the
procedurethepatientwasdischargedhomefromthehospital
tolerating an advancing diet. He died 4 months later from
Figure 2: CT angiography coronal plane reconstruction showing
the portal vein system with obstruction from the recurrent pancre-
atic tumor at the portal vein conﬂuence (white arrow) and resulting
gastric and small bowel varices (black arrows).
Figure 3: Isolated portal system reconstruction deﬁning the
obstruction of the splenic vein at the portal vein conﬂuence (block
arrow) and clear conﬁrmation of the subsequent gastric and small
bowel varices (normal arrows).
natural progression of the malignancy. During this time, he
did not experience any additional episodes of GI bleeding
and remained relatively comfortable.
3. Discussion
Pancreatic cancer remains an oncologic challenge where
early metastatic relapse after complete resection is fre-
quently encountered. Sperti et al reported local and hepatic
recurrence rates of 72% and 62%, respectively, in patients
undergoing curative resection [4]. In the current study,HPB Surgery 3
Figure 4: Transhepatic portography characterizing the splenic vein
obstruction from the recurrent pancreatic tumor (white arrow)
with dilated varices proximally (black arrows).
Figure 5: Transhepatic portography after endovascular stent place-
ment and balloon dilation of the splenic vein obstruction (white
arrow) with dramatic decompression of the proximal varices (black
arrows).
our patient presented with a 2.5cm mass arising in the
background of pancreatic divisum and chronic pancreati-
tis. On ﬁnal pathology, he was found to have Stage I
T1N0 disease. The only poor prognostic factor identiﬁed
was perineural involvement. In a recent review, perineural
invasion was noted in 70% of patients and was associated
with a signiﬁcantly poorer median disease free survival of
16.2 months [5]. We believe that the recurrence noted in
our patient involved the extrapancreatic nerve plexus [6].
Alternatively, the site of recurrence may be argued secondary
to occult multifocal pancreatic cancer. The lack of pancreatic
intraepithelial neoplasia within the resected specimen and
numerous follow-up imaging is against the later argument.
Extrahepaticportalvenousobstructionaccountsfor5%–
10% of all cases of portal hypertension, with neoplasms
such as hepatocellular carcinoma and pancreatic and biliary
cancer accounting for 15%–24% of those cases [3]. Cancer
can lead to thrombosis of the portal venous system through
a combination of factors including cancer-related pro-
thrombogenic changes, tumor invasion, periportal ﬁbrosis
following surgery or radiotherapy, or more commonly from
extrinsic compression or constriction from tumor mass [7,
8]. Other causes of portal hypertension from extrahepatic
occlusion or thrombosis include infection complicated by
peritonitis, liver abscess, biliary tract surgery, and congenital
abnormalities [9]. Coagulopathies that lead to thrombosis
and thrombophlebitis migrans can also be a cause [9].
Prehepatic portal hypertension from portal vein stenosis
or occlusion secondary to malignant invasion is a diﬃcult
entity to diagnose and treat. This diﬃculty is exempliﬁed
by the fact that occlusion of the portal vein frequently does
not produce an acute manifestation. The reasons are twofold
why the blocking of portal blood ﬂow, which accounts for
two thirds of the total hepatic supply, results in few clinical
manifestations. The ﬁrst is because of the compensatory
mechanism of vasodilation of the hepatic arterial system
occurs in response to a decrease in portal vein ﬂow [10].
T h es e c o n di sap r o c e s st e r m e dcavernous transformation,f o r
which is the rapid development of tortuous collateral veins
bypassing the thombosed or occluded portion of the portal
vein that will usually become apparent within a matter of
days [10]. Herein lies the manifestation most devastating to
patients with portal venous obstruction.
When symptoms do occur, they can present in a variety
of ways [8, 10–12]. The most frequent manifestation result-
ing in patient’s seeking medical attention is hematemesis or
melena from the development of varices in the esophagus,
stomach, small intestine, and colon, which can result in
severe gastrointestinal bleeding and ultimately death [8, 11].
Janssen et al. retrospectively evaluated 172 patients (27% of
patients had hepatobiliary or gastrointestinal malignancies)
with extrahepatic portal vein thrombosis and found that
an episode of bleeding from ruptured esophagogastric
varices was the initial manifestation in 52 (30%) patients
[12]. Furthermore, of the 130 patients tested, 104 patients
demonstrated esophageal varices and 4 percent of those
patients died from their variceal hemorrhage [12].
As exempliﬁed by our patient, these cases can be a diag-
nostic and treatment dilemma, with treatment options being
few due to rapid tumor growth and related diseases resulting
in a very poor prognosis. Historically, treatments for such
conditions have been radiation therapy or chemotherapy;
however, resolution of the signs and symptoms may have a
delayed period of eﬀect up to 3 weeks [13]. These patients
are typically not good surgical candidates due to their poor
clinical status and therefore are in need of less invasive
methods for palliating their symptoms. Endoscopic variceal
sclerotherapy has been eﬀective in treating varices of the
esophagus and stomach but are ineﬀective for bleeding
further down the gastrointestinal tract. By applying the
same physiology of esophagogastric varices to the small
bowel, some of these patients can be treated medically with
octreotide, propanolol, and other forms of therapy such
as chemoradiotherapy [14]. Even with these conservative
therapies patients still require multiple hospitalizations from
associated symptoms and suﬀer from prolonged episodes of
bleeding, with always the risk of sudden death. As physicians
treating cancer we should always seek ways in which to
palliate our patients with as little disability as possible, and4 HPB Surgery
as shown with our patient percutaneous placed endovascular
stents has permitted our ability to eﬀectively treat these
patients with this type of condition.
We report here the successful SV at the PV conﬂuence
stenting of a patient with active variceal bleeding due to
recurrent pancreatic cancer. A MEDLINE review of literature
yields a total of 64 reported cases of portal vein stent
placement, the ﬁrst of which was by Harville et al. in
1991 [15]. They were able to establish portal vein patency
and relief of massive lower GI hemorrhage from colonic
varices in a patient with portal hypertension caused by
extrahepatic obstruction from chronic pancreatitis. Mathias
et al. demonstrated successful use of this technique in a
p a t i e n tw i t hp o r t a lv e n o u ss t e n o s i sd u et oe n c a s e m e n tb y
pancreatic cancer resulting in portal venous hypertension
and variceal bleeding [16]. Portal hypertension was relieved
with no recurrent variceal bleeding during the 5 months
before the patient died [16]. Watanabe et al. have shown
in two patients with malignant portal stenosis that metallic
stent implantation can reduce portal pressures dramatically
resulting in normalization of liver function tests and reduc-
tion of ascites [13].
The largest series reported in literature is by Yamakodo
et al. where they were able to place stents into the portal
venous system via a percutaneous transhepatic route across
28 stenotic and 12 obstructive lesions [3]. They reported a
mean followup period of 11.9 months (range, 2–61 months),
during which 60% percent of the stents remained patent [3].
Stent occlusion was found in 40% of the patients, with a
mean period until stent occlusion of 3.7 months (range, 0.2–
16 months) clearly showing an eﬀective method of treatment
in patients with short life expectancies [3].
Extrahepatic portal venous obstruction can be a major
cause of portal hypertension and morbidity to these patients.
It seems that in a selected patient population portal venous
stents can be used aﬀectively to palliate the symptoms caused
by portal hypertension due to these types of conditions.
Future studies, like the one by Yamakodo et al. showing
that portal venous stent patency is prolonged when there
is not substantial splanchnic vein involvement, are needed
to further clarify and classify which group of patients with
malignant portal venous involvement would beneﬁt from
such therapy [11]. At this time, it seems appropriate to
consider stent placement when surgery is contraindicated,
life expectancy is short, or other conservative methods
of treatment have been exhausted. Portal venous stent
placement provides rapid decompression of varices and
palliation of symptoms with little morbidity to the patient
helpingtoimprovetheirqualityoflifeandprognosis.Wefeel
that it is important for physicians to be aware of the tools
available for palliation and add them to their armitarium
for the care of patients with such complex problems and
devastating diseases.
The presence of recurrence occurring at the superior
mesenteric/portal venous conﬂuence raises the question of
initial portal vein resection. Although the indication and
contraindication for portal vein resection has not universally
deﬁned, there are many reports addressing its beneﬁt [6, 17–
19]. The MD Anderson groups, who are known advocates of
portal vein resection, have recently reported that this patient
population have a higher likelihood of an R1 resection [20].
4. Conclusion
The treatment for patients with malignant superior
mesenteric/portal vein obstruction and associated bleeding
esophageal and gastric varies can prove to be diﬃcult, but as
we have shown endovascular stenting of the portal system is
an eﬀective treatment option.
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